RTI gets $5M in patent dispute

Texas-based Retractable Technologies (NYSE AMEX: RVP) will recover $5 million with prejudgment interest from Becton, Dickinson after receiving a permanent injunction and an order in its patent litigation involving the 1- and 3-mL Integra syringes.

The U.S. District Court for the Eastern District of Texas, Marshall Division entered judgment for RTI and rejected BD's counter claims for declaratory judgment of non-infringement, invalidity, and unenforceability.

The court ordered a permanent injunction for the Integra syringes at issue until the expiration of certain patents. However, the permanent injunction is stayed for the longer of the exhaustion of an appeal of this case or 12 months from the date of the order, which is May 19, 2010, according to an RTI statement.

RTI  manufactures the VanishPoint automated retraction safety syringes, blood collection devices, and IV catheters, that virtually eliminate healthcare worker exposure to accidental needlestick injuries.

Shares of Retractable Technologies added 5 cents, or 3 percent, to $1.70 in afternoon trading. Becton Dickinson shares climbed 37 cents to $71.86, ABC News reports.

- get RTI's statement
- read ABC News' coverage

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.